News

Celltrion, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), a biosimilar to EYLEA®, for the treatment of several major…
Read More...

Cidara Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational drug CD388 for the prevention of…
Read More...

Boehringer Ingelheim has received approval from the U.S. Food and Drug Administration (FDA) for its new oral therapy, JASCAYD (nerandomilast), for the treatment of idiopathic pulmonary…
Read More...

Turbine, a biotechnology company specializing in AI-based virtual disease modeling, has announced a collaboration with AstraZeneca to enhance the discovery of antibody-drug conjugates…
Read More...

Werewolf Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead candidate WTX-124, a conditionally activated…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals' Libtayo® (cemiplimab-rwlc) as the first adjuvant immunotherapy for adult patients with cutaneous…
Read More...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company focused on developing next-generation treatments for gout and tophaceous gout, has announced the successful closing of a…
Read More...

Algen Biotechnologies has entered a multi-target partnership with AstraZeneca aimed at speeding up the discovery of new therapeutic targets in immunology. The collaboration will…
Read More...

Milan-based biotech firm NanoPhoria Bioscience has announced the successful first close of its €83.5 million Series A funding round, marking a major step forward in its mission to…
Read More...

Oragenics, a clinical-stage biotech company focused on brain-targeted therapeutics, has announced a strategic collaboration with Receptor.AI, a drug profiling company leveraging…
Read More...

Affinia Therapeutics has announced the close of a $40 million Series C financing round to advance development of its lead gene therapy candidate, AFTX-201, for the treatment of BAG3…
Read More...

AstraZeneca and Daiichi Sankyo have announced breakthrough results from the Phase III TROPION-Breast02 trial, showing that their antibody drug conjugate Datroway (datopotamab…
Read More...

Chiesi Group and Arbor Biotechnologies have announced an exclusive global collaboration and licensing agreement to advance the development of innovative gene editing therapies for rare…
Read More...

Neurizon Therapeutics Limited has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational therapy, NUZ-001, a key step…
Read More...

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved the combination of Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and…
Read More...

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a promising anti-microtubule binding region-tau…
Read More...

Taysha Gene Therapies announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSHA-102, its intrathecally delivered AAV9 gene therapy…
Read More...

Halozyme Therapeutics has announced a definitive agreement to acquire Elektrofi, a biopharmaceutical company known for its breakthrough ultra-high concentration biologics delivery…
Read More...

Takeda Pharmaceutical Company has announced it will discontinue its cell therapy research and development efforts as part of a broader strategic portfolio prioritization. The company…
Read More...

Star Therapeutics has announced the closing of an oversubscribed $125 million Series D financing round to accelerate the development of its pipeline of antibody-based therapies,…
Read More...